Zelboraf Approval Hastened By FDA Officials Impressed With Early Efficacy
By
Mary Jo Laffler, Emily Hayes / Email the Authors / “The Pink Sheet” Aug. 22, 2011, Vol. 73, No. 34
New Products / Word Count: 2207 / Article # 00110822013
Executive Summary
Supported by robust data demonstrating knock-out response rates, Roche/Genentech’s Zelboraf (vemurafenib) has sailed through the FDA approval process, aided by a push from the agency.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.